ProNAi Therapeutics Inc (SRRA)

[©PROPHETABLE]

Here is why:

Our CEO, Dr. Nick Glover discusses our strategy going forward in webcasts available on our website (http://pronai.investorroom.com/).
We have a world-class drug development team in place with a proven track record, and significant capital with $130M cash at end of Q2. Our strategy going forward is to build a pipeline of oncology assets acquired though business development activities, and to advance these assets through development with the goal of obtaining regulatory approvals and commercializing these products if they prove successful in the clinic. By having a broad portfolio of candidates we aim to diversify risk and create a steady stream of milestones to deliver on.
We have already brought in the first asset in our new pipeline at low cost, PNT141. Additional assets are in-line for us to potentially license pending our scientific review.
We are managing our resources prudently and expect to have resources beyond 2017 with a pipeline capable of generating milestones within that runway.